6,713 reports of this reaction
4.4% of all DOCETAXEL ANHYDROUS reports
#2 most reported adverse reaction
MADAROSIS is the #2 most commonly reported adverse reaction for DOCETAXEL ANHYDROUS, manufactured by Hospira, Inc.. There are 6,713 FDA adverse event reports linking DOCETAXEL ANHYDROUS to MADAROSIS. This represents approximately 4.4% of all 152,096 adverse event reports for this drug.
Patients taking DOCETAXEL ANHYDROUS who experience madarosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MADAROSIS is moderately reported among DOCETAXEL ANHYDROUS users, representing a notable but not dominant share of adverse events.
In addition to madarosis, the following adverse reactions have been reported for DOCETAXEL ANHYDROUS:
The following drugs have also been linked to madarosis in FDA adverse event reports:
MADAROSIS has been reported as an adverse event in 6,713 FDA reports for DOCETAXEL ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
MADAROSIS accounts for approximately 4.4% of all adverse event reports for DOCETAXEL ANHYDROUS, making it one of the most commonly reported side effect.
If you experience madarosis while taking DOCETAXEL ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.